CLINICAL EVALUATION DASHMULARISHTA IN RESTORING NORMAL HEALTH OF FEMALES AFTER DELIVERY

CLINICAL EVALUATION OF THE EFFICACY OF DASHMULARISHTA IN RESTORING NORMAL HEALTH OF POSTPARTUM FEMALES

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/08/009278

Enrollment

100

Registered

2017-08-07

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Dabur Dashmularishta: Ayurvedic Polyherbal Formulation. Dose is 30 ml BD, oral for 8 weeks. Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: 1 Females with normal deliveries 2 Females between the ages of 18-40 years 3 Willingness to sign informed consent and to come for regular follow up examination as and when required.

Exclusion criteria

Exclusion criteria: History of complicated labour /caesarean section/any other complication related to pregnancy, like eclampsia, preeclampsia, Patients not willing to sign informed consent, Patients not willing to come for follow up when required, Patients participating in any other clinical trials, Patients with systemic diseases like diabetes mellitus, bleeding diathesis, TB, severe anemia( < 7gm %).

Design outcomes

Primary

Measure	Time frame
The primary objective of the study was for early resumption of daily activities of post partum females and Improvement the quality of life following deliveryTimepoint: 8 weeks	—

Secondary

Measure	Time frame
To assess the safety profile of Dabur DashmularishtaTimepoint: 8 weeks	—

Countries

India

Contacts

Public ContactDr JLN Sastry

Dabur India Limited

sasibhushan.vedula@dabur.com01203378405

Outcome results